Citigroup’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
Citigroup's DNLI Position: Q3 2026 in Review
Citigroup reduced its Denali Therapeutics (DNLI) stake by 32% in Q3 2026, selling an estimated $3.62M and leaving 332,788 shares worth $6.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1894.
Citigroup first reported a position in DNLI in Q1 2018 and has held it in 35 quarters since. The position peaked at $12.5M in Q2 2026. 284 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.
- Citigroup held 332,788 shares of Denali Therapeutics worth $6.88M as of Q3 2026.
- Citigroup sold 154,490 Denali Therapeutics shares in Q3 2026, an estimated $3.62M.
- Denali Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #1894 holding.
- Citigroup first reported a position in Denali Therapeutics in Q1 2018 and has held it in 35 quarters since.
- Citigroup's Denali Therapeutics position peaked at $12.5M in Q2 2026.
- 284 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.